Entering text into the input field will update the search result below

Immuneering highlights preclinical datasets from IMM-1-104 cancer treatment studies

Genetic Research, scientist viewing DNA information on screens

Andrew Brookes/Cultura via Getty Images

  • Immuneering (NASDAQ:IMRX) highlights three key preclinical datasets indicating the potential of its lead product candidate IMM-1-104.
  • IMM-1-104 is designed to be a highly selective dual-MEK inhibitor that further disrupts the kinase suppressor of RAS 1 and

Recommended For You

More Trending News

About IMRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
IMRX--
Immuneering Corporation